Life Science Research & Vertically Integrated California Cultivator Offers App to Help Consumers Track Cannabis Effects on Their Health and Wellness
VANCOUVER, British Columbia, March 02, 2022 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today the launch of the Company’s Journal App, designed to help cannabis users and patients track their consumption, and gain insight into how cannabis products affect their health and wellness.
“We’re proud to be one of the first and only companies to offer consumers a daily tracking solution that provides them a closer look at how their cannabis use affects their personal health and wellness,” said Doug Chloupek, CEO and Founder of Juva. “One of Juva’s primary goals is to expand our industry’s knowledge of the medicinal effects of cannabis from a scientific perspective. The Journal App provides a personal tracking solution for our customers and it gives Juva information that compliments the data we collect via our research registry.”
Through the Journal App, cannabis consumers and anyone who uses hemp-based cannabidiol (CBD) products can track their symptoms, medication use and results. Consumers can track a variety of health ailments, while documenting the products they consumed, the effect they had on their specific symptoms and any side effects that may occur.
“In all industries, data is king. Through both the Journal App and our WIRB-approved registry, we are curating one of the largest repositories of real-world data on the medical effects of cannabis use, including consumption behavior and perceived effectiveness. While we remain committed to the privacy of our users, the data we are collecting will be beneficial from a regulatory and scientific standpoint and adds significant value to Juva’s intellectual property portfolio,” added Chloupek. “All user info associated with the Journal App and the WIRB-approved registry is protected by the strictest patient privacy laws in the world, so participants can rest assured their entries are 100% confidential; any data imputed is anonymized for patient privacy.”
Those interested in downloading the Journal App can do so here: https://shopjuva.com/journalapp/
The Company is also running a WIRB-approved multi-year study through its cannabis research registry. Once completed Juva will have one of the largest data sets of its kind and be able to leverage the data in both its nutraceutical wellness, drug development and clinical programs. This real-world observational data, overseen by physicians and clinicians, will be presented to various regulatory bodies to show the potential therapeutic benefits of cannabis and hemp-derived compounds.
Juva Life also has a pharmaceutical research and life sciences division, with a goal of identifying the mode of action behind cannabis’ anecdotal ability to regulate inflammation. The Company recently identified non-cannabinoid compounds JUVA-019 and JUVA-041, on which the Company has filed patent applications and has conducted preclinical research showing the compound is effective as a stand-alone compound in inhibiting inflammation by modulating certain biomarkers in the body. JUVA-019 and JUVA-041, which the Company has nominated as drug candidates for further preclinical investigation, are currently advancing through phenotypic models of chronic diseases of aging.
ON BEHALF OF THE BOARD,
Doug Chloupek, CEO and Founder
Juva Life Inc.
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
As of 3:10 p.m. ET, Nvidia (NASDAQ: NVDA) shares have lost 2.6% of their value, Micron Technology (NASDAQ: MU) is down 4.5%, and Advanced Micro Devices (NASDAQ: AMD) is leading the whole pack lower — down 5.2%. The only real "news," so far as I can tell, is good news for Micron: the announcement that Fitch is upgrading Micron's debt rating to BBB, which moves the company's debt out of the "speculative" category and makes it "investment grade" — indeed, a "good credit quality."
"Dear stock market," Alex Butmanov toasted on a live broadcast, "you were close to us and interesting. Rest in peace, dear comrade.” The anchor was caught off-guard.
Alibaba Group Holding is probably “the cheapest company in the world” outside of Russia as investors put a high China risk premium on the e-commerce giant, according to Daniel O’Keefe, a managing director and portfolio manager at Artisan Partners. Speaking at a roundtable group discussion Tuesday with other value-oriented portfolio managers, O’Keefe said that Alibaba (ticker: BABA) is “one of the cheapest stocks I’ve ever seen, especially for a business of that quality with that financial strength.” The discussion, called Invaluable Insights, was sponsored by Ariel Investments and included John Rogers of Ariel, Bill Miller of Miller Value Partners, David Herro of Oakmark Funds, and Barron’s Roundtable member Mario Gabelli.
Shares of Nio (NYSE: NIO) were tumbling again Thursday after sliding Wednesday. Traders are likely reacting to recent news about supply chain problems at Ford and Rivian Automotive. The Chinese electric vehicle company's stock price was down by 8.6% as of 2:22 p.m. ET.
A screen of U.S. and European stocks produces a list of favored companies as NATO countries gear up to increase defense spending.
Family Wealth & Pension Management CEO Ian Weinberg joins Yahoo Finance Live to discuss safe haven assets like Treasuries, gold, and stocks amid inflation, market volatility, and Fed tightening.
The markets were already on shaky ground in 2022’s opening period, as the prospect of inflation and higher interest rates loomed large. But the volume has been turned up significantly now there is a full-scale war to contend with following Putin’s invasion of Ukraine. What does all this mean for the global markets? Asks Oppenheimer’s Chief Investment Strategist John Stoltzfus, before providing the answer: “Near-term volatility likely will persist on the landscape as global market participants we
Shares of Kroger (NYSE: KR) popped 11.6% to a record closing high of $55.10 on Thursday, following the release of the grocery leader's fourth-quarter results. Kroger's sales jumped 7.5% year over year to $33 billion. After adjusting for fluctuations in fuel prices, the grocery retailer's sales rose 3.7%.
There are plenty of fundamentally sound, low cost stocks out there for retail investors to consider. The key to success is to find stocks that are at or near the bottom of their cycle. Equity investment advisors will always tell you that ‘timing the market’ is impossible, and they’re right – but timing is still important for success. Investors need to buy into low prices, and to do that, they need to know when prices are low. This doesn’t necessarily mean low in absolute dollar terms, but low re
If full-blown stagflation is here, strategists say the best moves are into commodities, playable via miners, oil companies and fertilizer manufacturers. Then there’s cash.
Shares of Veeva Systems (NYSE: VEEV) were sinking 16.9% as of 10:53 a.m. ET on Thursday. It posted adjusted earnings per share of $0.90, a 15% increase. Veeva forecast adjusted earnings per share of between $0.91 and $0.92 in the first quarter.
Yahoo Finance's Jared Blikre breaks down the quarterly earnings results for Gap and Costco.
LSE halts transactions in firms hit by sanctions and warns more may follow
Following a rebound in the stock of Tesla (NASDAQ: TSLA) in late February that took it from below $800 closer to $900, the electric-vehicle (EV) maker's shares are taking a breather on Thursday. The decline is likely primarily due to a bearish day for the overall market on Thursday, namely the tech-heavy Nasdaq Composite. Shares of Tesla have had a rough year so far.
What happened Just Eat Takeaway.com (NASDAQ: GRUB) shareholders lost ground to the market on Thursday as the stock fell 13% by 3 p.m. ET compared to a 0.1% increase in the S&P 500. The slump followed the global food delivery specialist's fourth-quarter earnings report, which came up short of some investors' expectations.
When building a retirement portfolio, you have many options to choose from. Stocks, bonds, mutual funds and exchange-traded funds (ETFs) can all be part of a basket of investments that will help you make sure you’re able to take care … Continue reading → The post How Much Does a $100,000 Annuity Pay Per Month? appeared first on SmartAsset Blog.
Here's another cold, hard truth that many proponents of penny stocks don't tell you: Many low-priced shares stay low for a very long time.
Intel Corp. may have gotten a callout in President Joe Biden's State of the Union address earlier in the week, but on Thursday it fell further down Morgan Stanley's list of chip names.
Retailing giant Costco reported a strong fiscal second quarter, but beating analyst estimates hasn't seemed to satisfy investors.
The Dow Jones rose despite a Fed official saying there is need for more rate hikes, Vladimir Putin insisted the Ukraine war was going well.